Agents
First-Generation Antipsychotic Agents (see Antipsychotic Agents)
- General Comments
- First-Generation Antipsychotic Agents Have a Higher Incidence of Extrapyramidal Adverse Effects and Tardive Dyskinesia, as Compared to the Second-Generation Antipsychotic Agents
- Low-Potency Agents: higher anticholinergic side effects, lower extrapyramidal side effects
- Chlorpromazine (Largactil, Thorazine) (see Chlorpromazine)
- Thioridazine (Mellaril, Novoridazine, Thioril) (see Thioridazine)
- High-Potency Agents: lower anticholinergic side effects, higher extrapyramidal side effects
- Fluphenazine (Prolixin) (see Fluphenazine)
- Haloperidol (Haldol) (see Haloperidol)
- Loxapine (Loxitane, Adasuve) (see Loxapine)
- Perphenazine (Trilafon) (see Perphenazine)
- Pimozide (Orap) (see Pimozide)
- Thiothixene (Navane) (see Thiothixene)
- Trifluoperazine (Stelazine) (see Trifluoperazine)
Second-Generation Antipsychotic Agents (Atypical Antipsychotics) (see Antipsychotic Agents)
- General Comments
- Second-Generation Antipsychotic Agents are Generally Believed to Have a Lower Incidence of Extrapyramidal Adverse Effects and Tardive Dyskinesia, as Compared to the First-Generation Antipsychotic Agents: likely related to the weaker affinity of these agents for the dopamine D2 receptor
- However, Other Studies Have Suggested that the Differences Between First and Second-Generation Antipsychotics with Regard to Extrapyramidal Side Effects May Be More Minimal than Has Been Previously Believed (Lancet, 2003) [MEDLINE]
- Aripiprazole (Abilify) (see Aripiprazole)
- Asenapine (see Asenapine)
- Brexpiprazole (Rexulti) (see Brexpiprazole)
- Cariprazine (see Cariprazine)
- Clozapine (Clozaril) (see Clozapine)
- Epidemiology
- Clozapine Has a Low Risk of Acute Extrapyramidal Effects, as Well as a Rare Association with Tardive Dyskinesia
- Epidemiology
- Iloperidone (Fanapt, Zomaril) (see Iloperidone)
- Lurasidone (Latuda) (see Lurasidone)
- Olanzapine (Zyprexa) (see Olanzapine)
- Epidemiology
- Highest Risk of Tardive Dyskinesia Among the Second-Generation Antipsychotics
- Epidemiology
- Paliperidone (Invega) (see Paliperidone)
- Pimavanserin (Nuplazid) (see Pimavanserin)
- Quetiapine (Seroquel) (see Quetiapine)
- Risperidone (Risperdal) (see Risperidone)
- Epidemiology
- Highest Risk of Tardive Dyskinesia Among the Second-Generation Antipsychotics
- Epidemiology
- Ziprasidone (Geodon) (see Ziprasidone)
References
- xxx